Biotoxtech바이오톡스텍
086040 · KOSDAQ · ₩086040 · 바이오톡스텍
₩2,110▲ ₩30 (1.44%)End-of-day · Oct 28, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | 14.2% | 12.5% | 6.2% | 5.8% | 33.5% | 35.0% |
| Operating margin | −6.6% | −10.2% | −21.5% | −25.1% | 2.1% | 12.2% |
| Net margin | −7.6% | 2.5% | −15.5% | −14.9% | 7.3% | 20.9% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | +11.6% | +13.7% | +26.7% | −12.5% | +9.4% | — |
| Operating income growth | +28.0% | +45.8% | −8.4% | −1,123.3% | −80.8% | — |
| Net income growth | −443.6% | +118.1% | −31.8% | −279.0% | −61.7% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −11.0% | 2.9% | −14.0% | −10.2% | 6.4% | 17.3% |
| Return on assets | −4.9% | −1.2% | −8.9% | −6.6% | 1.4% | 7.7% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 491.3% | 312.2% | 294.5% | 204.8% | 183.3% | 116.8% |
| Net debt to equity | 119.1% | 60.3% | 89.3% | 33.9% | 51.1% | 19.5% |
| Current ratio | 54.2% | 56.9% | 71.7% | 86.1% | 82.5% | 82.5% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Biotoxtech / 바이오톡스텍 / 086040 / KRX:086040
Source: KRX statistical information